Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Membrane associated collagen XIII promotes cancer metastasis and enhances anoikis resistance.

Zhang H, Fredericks T, Xiong G, Qi Y, Rychahou PG, Li JD, Pihlajaniemi T, Xu W, Xu R.

Breast Cancer Res. 2018 Oct 1;20(1):116. doi: 10.1186/s13058-018-1030-y.

2.

Development of murine bariatric surgery models: lessons learned.

Frohman HA, Rychahou PG, Li J, Gan T, Evers BM.

J Surg Res. 2018 Sep;229:302-310. doi: 10.1016/j.jss.2018.04.022. Epub 2018 May 10.

3.

Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer.

Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, Sivakumaran TA, Fan T, Moseley H, Gao T, Lee EY, Weiss HL, Heuer TS, Kemble G, Evers M.

Oncotarget. 2018 May 15;9(37):24787-24800. doi: 10.18632/oncotarget.25361. eCollection 2018 May 15.

4.

The role of ROS generation from magnetic nanoparticles in an alternating magnetic field on cytotoxicity.

Wydra RJ, Rychahou PG, Evers BM, Anderson KW, Dziubla TD, Hilt JZ.

Acta Biomater. 2015 Oct;25:284-90. doi: 10.1016/j.actbio.2015.06.037. Epub 2015 Jul 2. Erratum in: Acta Biomater. 2016 Mar;33:322-3.

5.

RNA Nanoparticles Derived from Three-Way Junction of Phi29 Motor pRNA Are Resistant to I-125 and Cs-131 Radiation.

Li H, Rychahou PG, Cui Z, Pi F, Evers BM, Shu D, Guo P, Luo W.

Nucleic Acid Ther. 2015 Aug;25(4):188-97. Epub 2015 May 27.

6.

Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.

Xiong G, Deng L, Zhu J, Rychahou PG, Xu R.

BMC Cancer. 2014 Jan 2;14:1. doi: 10.1186/1471-2407-14-1.

7.

Engineered nanopore of Phi29 DNA-packaging motor for real-time detection of single colon cancer specific antibody in serum.

Wang S, Haque F, Rychahou PG, Evers BM, Guo P.

ACS Nano. 2013 Nov 26;7(11):9814-22. doi: 10.1021/nn404435v. Epub 2013 Oct 30.

8.

Murine portal vein catheterization to analyze liver-directed therapies.

Valentino JD, Rychahou PG, Mustain WC, Elliott VA, Evers BM.

J Surg Res. 2013 Dec;185(2):690-6. doi: 10.1016/j.jss.2013.06.051. Epub 2013 Jul 17.

9.

Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.

Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, Townsend CM Jr, Liu C, Evers BM.

Carcinogenesis. 2013 May;34(5):953-61. doi: 10.1093/carcin/bgt018. Epub 2013 Jan 25.

10.

Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers.

Haque F, Shu D, Shu Y, Shlyakhtenko LS, Rychahou PG, Evers BM, Guo P.

Nano Today. 2012 Aug;7(4):245-257.

11.

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.

Valentino JD, Elliott VA, Zaytseva YY, Rychahou PG, Mustain WC, Wang C, Gao T, Evers BM.

Surgery. 2012 Aug;152(2):277-85. doi: 10.1016/j.surg.2012.05.006.

12.

Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.

Dong C, Wu Y, Wang Y, Wang C, Kang T, Rychahou PG, Chi YI, Evers BM, Zhou BP.

Oncogene. 2013 Mar 14;32(11):1351-62. doi: 10.1038/onc.2012.169. Epub 2012 May 7.

13.

G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer.

Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, Evers BM, Zhou BP.

J Clin Invest. 2012 Apr;122(4):1469-86. doi: 10.1172/JCI57349. Epub 2012 Mar 12.

14.

Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.

Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, Morris AJ, Sunkara M, Weiss HL, Lee EY, Evers BM.

Cancer Res. 2012 Mar 15;72(6):1504-17. doi: 10.1158/0008-5472.CAN-11-4057. Epub 2012 Jan 19.

15.

Inhibition of aldose reductase prevents colon cancer metastasis.

Tammali R, Reddy AB, Saxena A, Rychahou PG, Evers BM, Qiu S, Awasthi S, Ramana KV, Srivastava SK.

Carcinogenesis. 2011 Aug;32(8):1259-67. doi: 10.1093/carcin/bgr102. Epub 2011 Jun 3.

16.

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.

Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, Evers BM.

Cancer Res. 2011 May 1;71(9):3246-56. doi: 10.1158/0008-5472.CAN-10-4058. Epub 2011 Mar 23.

17.

The role of neurotensin in physiologic and pathologic processes.

Mustain WC, Rychahou PG, Evers BM.

Curr Opin Endocrinol Diabetes Obes. 2011 Feb;18(1):75-82. doi: 10.1097/MED.0b013e3283419052. Review.

PMID:
21124211
18.

VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, Townsend CM Jr, Evers BM.

Int J Cancer. 2011 Mar 1;128(5):1045-56. doi: 10.1002/ijc.25441.

19.

Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.

Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM.

J Am Coll Surg. 2010 May;210(5):767-76, 776-8. doi: 10.1016/j.jamcollsurg.2009.12.008.

20.

Hydrodynamic delivery protocols.

Rychahou PG, Evers BM.

Methods Mol Biol. 2010;623:189-95. doi: 10.1007/978-1-60761-588-0_12.

PMID:
20217552
21.

PTEN loss induces epithelial--mesenchymal transition in human colon cancer cells.

Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou Y, Rychahou PG, Evers BM.

Anticancer Res. 2009 Nov;29(11):4439-49.

22.

Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.

Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T, Evers BM.

Clin Cancer Res. 2009 Dec 1;15(23):7207-16. doi: 10.1158/1078-0432.CCR-09-1249. Epub 2009 Nov 24.

23.

Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion.

Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP.

Cancer Cell. 2009 May 5;15(5):416-28. doi: 10.1016/j.ccr.2009.03.016.

24.

Development and characterization of a novel in vivo model of carcinoid syndrome.

Jackson LN, Chen LA, Larson SD, Silva SR, Rychahou PG, Boor PJ, Li J, Defreitas G, Stafford WL, Townsend CM Jr, Evers BM.

Clin Cancer Res. 2009 Apr 15;15(8):2747-55. doi: 10.1158/1078-0432.CCR-08-2346. Epub 2009 Mar 31.

25.

Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH, Evers BM.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20315-20. doi: 10.1073/pnas.0810715105. Epub 2008 Dec 15.

26.

Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma.

Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM, Chung DH.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12891-6. doi: 10.1073/pnas.0711861105. Epub 2008 Aug 27.

27.

PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy.

Jackson LN, Larson SD, Silva SR, Rychahou PG, Chen LA, Qiu S, Rajaraman S, Evers BM.

Am J Physiol Gastrointest Liver Physiol. 2008 Jun;294(6):G1401-10. doi: 10.1152/ajpgi.00062.2008. Epub 2008 Apr 3.

28.

N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH.

Oncogene. 2008 Jun 26;27(28):3999-4007. doi: 10.1038/onc.2008.15. Epub 2008 Feb 18.

29.

PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.

Shen X, Rychahou PG, Evers BM, Falzon M.

Cancer Lett. 2007 Dec 18;258(2):241-52. Epub 2007 Oct 26.

30.
31.

Effectiveness of siRNA uptake in target tissues by various delivery methods.

Larson SD, Jackson LN, Chen LA, Rychahou PG, Evers BM.

Surgery. 2007 Aug;142(2):262-9.

32.

Bombesin induces angiogenesis and neuroblastoma growth.

Kang J, Ishola TA, Baregamian N, Mourot JM, Rychahou PG, Evers BM, Chung DH.

Cancer Lett. 2007 Aug 18;253(2):273-81. Epub 2007 Mar 26.

33.

RNA interference: mechanisms of action and therapeutic consideration.

Rychahou PG, Jackson LN, Farrow BJ, Evers BM.

Surgery. 2006 Nov;140(5):719-25. Review. No abstract available.

PMID:
17084714
34.

MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.

Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH.

Biochem Biophys Res Commun. 2006 Dec 8;351(1):192-7. Epub 2006 Oct 12.

35.

Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.

Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM.

Ann Surg. 2006 Jun;243(6):833-42; discussion 843-4.

36.

Novel cross talk of Kruppel-like factor 4 and beta-catenin regulates normal intestinal homeostasis and tumor repression.

Zhang W, Chen X, Kato Y, Evans PM, Yuan S, Yang J, Rychahou PG, Yang VW, He X, Evers BM, Liu C.

Mol Cell Biol. 2006 Mar;26(6):2055-64.

37.
38.

Proteomic analysis of colonic myofibroblasts and effect on colon cancer cell proliferation.

Chen AL, Soman KV, Rychahou PG, Luxon BA, Evers BM.

Surgery. 2005 Aug;138(2):382-90.

PMID:
16153451
39.

Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice.

Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC.

Transplant Proc. 2005 May;37(4):1880-4.

PMID:
15919492
40.

Aging is associated with decreased pancreatic acinar cell regeneration and phosphatidylinositol 3-kinase/Akt activation.

Watanabe H, Saito H, Rychahou PG, Uchida T, Evers BM.

Gastroenterology. 2005 May;128(5):1391-404.

PMID:
15887120
41.

Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers.

Murillo CA, Rychahou PG, Evers BM.

Surgery. 2004 Aug;136(2):143-9.

PMID:
15300173

Supplemental Content

Loading ...
Support Center